Table 5 Cost analysis in modified intention-to-treat patients grouped as defined per bacteriologic documentation (visit 2)
Group I (n = 113, 46.3%) | Group II (n = 14, 5.7%) | Group III (n = 38, 15.6%) | Group IV (n = 56, 23.0%) | Group V (n = 23, 9.4%) | Overall (n = 244, 100%) | Kruskal–Wallis P value | |
|---|---|---|---|---|---|---|---|
Hospital admission (days) | 23.8 (39.9) | 19.9 (19.9) | 22.1 (36.0) | 14.9 (19.0) | 33.8 (81.2) | 22.3 (40.9) | 0.46 |
ICU admission (days) | 20.5 (34.1) | 34.0 (32.2) | 36.7 (24.2) | 23.7 (14.5) | 17.8 (79.0) | 24.3 (36.4) | <0.001 |
Costs of hospitalization in the general ward (€) | 4,983.40 (8,754.20) | 4,160.47 (4,461.11) | 4,835.13 (8,023.24) | 2,983.81 (4,164.14) | 7,264.92 (8.754.20) | 4,669.23 (8,971.35) | 0.44 |
Costs of ICU admission (€) | 6,725.70 (11,412.94) | 11,469.22 (10,872.13) | 12,055.11 (8,283.93) | 7,860.99 (4,965.19) | 5,749.28 (26,069.12) | 7,996.38 (12,182.74) | 0.001 |
Antibiotic acquisition costs (€) | 539.98 (2,636.00) | 533.03 (622.62) | 487.49 (1,002.59) | 322.06 (300.38) | 360.09 (446.92) | 464.44 (1,850.30) | 0.97 |
Other therapeutic and diagnostic procedures (€) | 631.26 (462.19) | 591.61 (278.65) | 853.59 (531.50) | 652.41 (399.60) | 855.75 (513.94) | 689.63 (463.63) | 0.04 |
Total costs per episode (€) | 12,880.35 (9,420.68) | 16,754.33 (10,977.94) | 18,231.32 (13,402.92) | 11,819.28 (7,007.02) | 14,230.04 (10,571.25) | 13,819.67 (10,041.06) | 0.01 |
Total daily costs (€) | 324.05 (102.29) | 327.16 (41.17) | 337.95 (46.27) | 332.19 (39.40) | 301.22 (156.78) | 326.07 (89.22) | 0.35 |